03.02.2017Kostengünstige Nachahmermedikamente setzen dem Pharmakonzern Astra-Zeneca zu. Der Umsatz sank 2016 um sieben Prozent. Das Unternehmen hofft nun auf neue Medikamente, etwa gegen Lungenkrebs. (...)
02.02.2017Die Europäische Kommission will in diesem Sommer einen neuen europäischen Aktionsplan gegen die wachsende Antibiotikaresistenz vorlegen. Dafür bittet sie Behörden, Interessenvertreter und Bürger – insbesondere Ärzte – um Mithilfe. In einer Konsultation sammelt die Kommission bis zum 28. April Vorschläge dazu, wie die Europäische Union (EU) die Mitgliedstaaten am besten dabei unterstützen kann, gegen die wachsende Antibiotikaresistenz vorzugehen. (...)
02.02.2017Das Informationssystem Versorgungsdaten (Datentransparenz) ist im Jahre 2014 gestartet. Ein Datenschatz aller rund 70 Millionen gesetzlich Versicherten in Deutschland ist seither verfügbar. Dieser beinhaltet u. a. Angaben über ambulante und stationäre Diagnosen sowie zur ambulanten Arzneimittelversorgung. Im Jahre 2017 stellt sich die Frage was diese Daten tatsächlich bringen? Und vor allem was das für Daten sind – diese sogenannten Routinedaten. (...)
02.02.2017Azi Torkamani is eight months pregnant and working 12-hour shifts at St. Joseph’s Hospital in Syracuse, New York. She’s a resident physician in family medicine. Some days she has so many patients she doesn’t have time to stop and eat lunch; she eats as she walks from floor to floor treating patients. On Monday, as she took rounds in the family medicine clinic, she was distracted by a nagging worry: How am I going to manage once the baby is born? This was not the normal worry of a first time mother. Torkamani is Iranian—and, in an instant, President Trump’s new immigration ban upended her family’s future.´(...)
02.02.2017Am Ende zog er wieder den Kürzeren. Ob beim US-Krebsspezialisten Medivation oder zuletzt bei Europas größtem Biotechunternehmen Actelion – in beiden Übernahmewettläufen musste sich Sanofi-Chef Olivier Brandicourt der Konkurrenz geschlagen geben. (...)
02.02.2017Bei der Entstehung von Krebs laufen die genetischen Programme einer Zelle aus dem Ruder. Während Tumore von Erwachsenen viele verschiedene DNA-Mutationen in sich tragen, die den Krankheitsverlauf beeinflussen, sind solche genetischen Defekte bei Kinderkrebs viel seltener. (...)
02.02.2017Research and Markets has announced the addition of the "Vaccine Delivery Markets for Microneedle Devices" report to their offering. Vaccines are recognized as one of the most significant healthcare developments in the last one hundred years. In spite of their role in improving quality-of-life and drastically reducing the level of morbidity and mortality from infectious diseases, the ability of healthcare and state institutions to maximize access to many millions of undeserved people has still not been realized. This is a complex picture that is characterized by significant regional and socioeconomic factors. (...)
02.02.2017A newly launched pluripotent stem cell (PSC) medium has been designed to respond to the latest challenges in stem cell research, showing improved flexibility and performance in modern applications like gene editing, single cell passaging and reprogramming. Researchers in these fields no longer have to adjust protocols or experiments to use media originally formulated for older applications. Thermo Fisher Scientific announced the launch of the Gibco™ StemFlex™ Medium today, along with key data and user experiences from beta testing sites speaking to the improvements the medium brings to the field. (...)
02.02.2017Research and Markets has announced the addition of the "Seasonal Influenza Vaccines - 5EU Drug Forecast and Market Analysis to 2025" report to their offering. A quadrivalent formulation of Intanza Intradermal is anticipated to be launched in the EU, following the launch of quadrivalent Fluzone Intradermal in the US. The sales of quadrivalent Intanza Intradermal are expected to increase to $1.5m in 2025. (...)
02.02.2017DUBLIN--(BUSINESS WIRE)--Research and Markets has announced the addition of the "Lung Injury - Pipeline Insights, 2017" drug pipelines to their offering. Lung Injury - Pipeline Insights, 2017 provides in depth insights on the pipeline drugs and their development activities around the Lung Injury. The report covers the product profiles in various stages of development including Discovery, Pre-clinical, IND, Phase I, Phase II, Phase III and Preregistration. (...)
Sie sehen Artikel 17981 bis 17990 von insgesamt 19790